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We discuss our recent findings on the increase, in chronic myeloid leukemia patients treated with imatinib, of B1
lymphocytes producing IgM anti-O-linked sugars expressed by leukemic cells, paralleled by increased B-stimulating
cytokines. We propose that one important effect of imatinib treatment is due to the remodelling of bone marrow
microenvironment.
In the last years, tyrosine kinases have
become the major targets of anti-cancer
drugs. In particular, imatinib mesylate, an
ATP competitive inhibitor of the consti-
tutively activated ABL1 tyrosine kinase of
the BCR-ABL oncoprotein, is approved
for the treatment of chronic myelogenous
leukemia (CML) in chronic phase; recent
updates of the phase 3 International
Randomized Study of Interferon and
STI571 (IRIS) trial have confirmed both
long-term efficacy and safety of the treat-
ment, with an estimated overall survival
rate of 86%.
1 However, resistance to
imatinib can occur, or develop during
treatment, leading to the failure of the
therapy and highlighting the need of early
markers of clinical response in order to
address alternative treatments. Of course, a
deeper understanding of the mechanisms
underlying the function of the drug would
be of help. Resistance is usually due to
point mutations in the BCR-ABL ATP-
binding site, that impede the binding of
imatinib.
1,2 Nevertheless, other mechan-
isms have been reported, such as BCR-
ABL gene amplification, aberrations in
other oncogenic signaling pathways, and
the persistence of leukemic stem cells.
2
Extrinsic factors have also been hypothe-
sized, including multidrug resistance and
microenvironmental factors,
2 pointing to
the possibility that imatinib action is not
limited to the leukemic cell population.
There is increasing evidence that the
response to imatinib mesylate is also linked
to the immune system with production of
antineoplastic cytokines and activation of
immune cell function by creating a bridge
between innate and adaptive immunity.
3
In a recent paper,
4 we reported that in
CML patients responding to imatinib
treatment clinical and cytogenetic response
is paralleled or preceded by early cytolo-
gical, phenotypic and molecular changes in
the bone marrow, involving the B cell
compartment, that are not detectable in
non responder patients. In particular, a
raise in CD20
+ B lymphocytes, coexpres-
sing CD5 and bearing surface (s)IgM, is
evidenced as early as 3 mo after the
beginning of therapy and persists up to
6–9 mo. This population of cells is
antibody-secreting, as an increase of IgM
is measured in the bone marrow plasma of
responder patients. Of note, this IgM
fraction contains antibodies which are
reactive with O-linked olygosaccharides
expressed by leukemic cells and capable to
kill them by a complement-independent
mechanism. Such antibodies, described in
the sera of solid cancer patients, resemble
the so called “natural antibodies,” that are
indeed produced by CD5
+ B lymphocytes,
also known as B1 lymphocytes, and in
healthy donors mainly involved in anti-
bacterial responses.
5,6
Thus, administration of imatinib mesy-
late can actually contribute to an “immu-
nologic bridge,” that functions exploiting
natural antibodies to activate an anti-
tumor reaction. How does it happen and
what is the mechanism that leads to the
stimulation of B1 cells? In the bone
marrow of responder patients, the pro-
duction of the stromal-derived factor-1
(SDF-1) and of the B lymphocyte activ-
ating factor of the tumor necrosis factor
family (BAFF), both involved in normal
B cell development and maturation,
7 is
induced by imatinib, at variance with non
responder patients. Thus, imatinib seems
to be capable of modulating the bone
marrow microenvironment leading to con-
ditions favorable to B cell differentiation.
It is tempting to speculate that imatinib
treatment is able to “reset” the bone
marrow microenvironment, involving stro-
mal and/or endothelial cells possibly res-
ponsible for SDF-1 and BAFF production,
that, in turn, would enhance the B cell
compartment. This might be due to the
therapeutic effects exerted by imatinib on
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the myeloid malignant progenitors,
8 that
would be substituted by normal precur-
sors, capable of repopulating the bone
marrow with normal stromal as well as
normal myeloid cells. This hypothesis
seems to be also supported by our finding
that in the bone marrow of responder
patients, transcription of the bone
morphogenetic proteins (BMP)2 and
BMP7, both related to SDF-1 synthesis,
are increased. Effects of imatinib on the
osteoblastogenesis and bone marrow
remodelling, mediated by BMP2, have
been recently reported;
9 moreover,
BAFF synthesis and release by normal
myeloid cells has been described.
9
Also, SDF-1 has been shown to block




remains to be defined the contribution
given in vivo by the CD20
+CD5
+ IgM-
secreting B cells population observed in
responder patients to the clearance of
leukemic cells, they would represent the
enhancement of B cell maturation and
function in a restored bone marrow,
as an early sign of the response to the
treatment.
We conclude that imatinib mesylate
significantly contributes to the renewal of
the whole bone marrow microenviron-
ment, due to a rescue of healthy progeni-
tors, capable of give rise to a normal
stromal compartment, composed of stromal
cells, fibroblasts, osteoblasts and endo-
thelial cells; this restored microenviron-
ment would lead to the development of
the observed B cell population producing
tumor-reactive IgM, through the enhanced
production of BMP, BAFF and SDF-1
(Fig.1). These changes are indeed docu-
mented in the bone marrow and sera of
responder patients and transiently detect-
able for a period of up to 6–9 mo, by
which time the resetting process would
be concluded, as proved by the stability
of the clinical, cytogenetic and molecular
response. As a statistically significant
correlation to the clinical, cytogenetic
and molecular response was found, we
propose that the detection of IgM
+ B cells
and the measurement of cytokines in the
bone marrow before and during treat-
ment may contribute to the early identi-
fication of responder and non responder
patients, and help in the choice and/or
design of alternative therapeutic strategies.
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Figure1. Model for an additional mechanism of action of imatinib mesylate. Imatinib mesylate would contribute to the renewal of the whole bone
marrow microenvironment, due to the “normalization” of hematopoietic precursors, able to give rise to healthy bone marrow stromal cells (BMSC),
fibroblasts (FB), osteoblasts (OB) and endothelial cells (EC), thus rebuilding the BM “niche.” Normal production of bone morphogenetic proteins (BMP),
B lymphocyte activating factor of the tumor necrosis factor family (BAFF) and stromal derived factor-1 (SDF-1) by normal BMSC, FB, EC, would remodel
the microenvironment and participate into the development of the B cell population producing tumor-reactive IgM.
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